Compare TCX & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCX | PLX |
|---|---|---|
| Founded | 1992 | 1993 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3M | 204.9M |
| IPO Year | 1996 | 1998 |
| Metric | TCX | PLX |
|---|---|---|
| Price | $20.32 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 29.5K | ★ 560.5K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $384,728,000.00 | $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $16.65 |
| P/E Ratio | ★ N/A | $25.34 |
| Revenue Growth | 8.03 | ★ 35.41 |
| 52 Week Low | $13.27 | $1.32 |
| 52 Week High | $23.38 | $3.10 |
| Indicator | TCX | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 38.71 |
| Support Level | $20.63 | $1.68 |
| Resistance Level | $22.26 | $1.78 |
| Average True Range (ATR) | 0.92 | 0.09 |
| MACD | -0.18 | 0.01 |
| Stochastic Oscillator | 17.66 | 43.48 |
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. Geographically company operates in USA, Canada and Europe.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.